|Budget Amount *help
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2020: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2019: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2018: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
|Outline of Final Research Achievements
Tumor endothelial cells from human clinical tumors and normal endothelial cells from non-cancerous portions were isolated and cultured. FACS analysis and RT-PCR confirmed the establishment of highly pure primary cultured cells. The hTERT gene was transfected into these primary cultured cells, and more than 50 generations of passages were possible. The transgenic cells maintained a endothelial cell phenotype. The transgenic cells retained the phenotype of endothelial cells and the characteristic differences in gene expression observed in primary cultured cells were also retained, and it was confirmed that the cells met the conditions for use in cell-based high through-put assays. We are validating the inhibitors found by screening and verifying in the preclinical models.